Literature DB >> 17132090

Characterization of frequently deleted 6q locus in prostate cancer.

Mei Sun1, Vasantha Srikantan, Lanfeng Ma, Jia Li, Wei Zhang, Gyorgy Petrovics, Mazen Makarem, Jeffrey W Strovel, Stephen G Horrigan, Meena Augustus, Isabell A Sesterhenn, Judd W Moul, Settara Chandrasekharappa, Zhiqiang Zou, Shiv Srivastava.   

Abstract

The long arm of chromosome 6 is frequently deleted in diverse human neoplasms. Our previous study showed a minimum deletion region between markers D6S1056 and D6S300 on chromosome 6q in primary prostate cancer (CaP). In this study, we further refined a 200-kb minimal region of deletion (6qTSG1) centered around D6S1013 marker. The 6qTSG1 transcripts contained complex multiple splicing variants with low or absent expression in CaP cells. None of the transcripts identified contained open reading frames that code for a protein in the NCBI database. The expression of 6qTSG transcripts revealed interesting hormonal regulation relevant to CaP biology. Expression of 6q TSG transcript was induced in LNCaP cells that were cultured in charcoal-stripped serum medium suggesting an upregulation of 6qTSG transcript by androgen ablation and cell growth inhibition/apoptosis. Induction of 6qTSG1 expression in response to androgen ablation was abrogated in androgen-independent derivatives of LNCaP cells. In summary, we have defined a candidate CaP suppressor locus on chromosome 6q16.1, and deletions of this locus are frequently associated with prostate tumorigenesis. In the light of emerging role of noncoding RNAs in cancer biology including CaP, future investigations of 6qTSG11 locus is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132090     DOI: 10.1089/dna.2006.25.597

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  7 in total

1.  A novel LZAP-binding protein, NLBP, inhibits cell invasion.

Authors:  Junhye Kwon; Hyun Jung Cho; Seung Hun Han; Jin Gu No; Jae Young Kwon; Hongtae Kim
Journal:  J Biol Chem       Date:  2010-02-17       Impact factor: 5.157

2.  A novel C53/LZAP-interacting protein regulates stability of C53/LZAP and DDRGK domain-containing Protein 1 (DDRGK1) and modulates NF-kappaB signaling.

Authors:  Jianchun Wu; Guohua Lei; Mei Mei; Yi Tang; Honglin Li
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

Review 3.  The structure and function of NKAIN2-a candidate tumor suppressor.

Authors:  Shan-Chao Zhao; Bo-Wei Zhou; Fei Luo; Xueying Mao; Yong-Jie Lu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma.

Authors:  Stefan Fritz; Carlos Fernandez-del Castillo; Mari Mino-Kenudson; Stefano Crippa; Vikram Deshpande; Gregory Y Lauwers; Andrew L Warshaw; Sarah P Thayer; A John Iafrate
Journal:  Ann Surg       Date:  2009-03       Impact factor: 12.969

5.  Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.

Authors:  Christoph Burdelski; Laura Borcherding; Martina Kluth; Claudia Hube-Magg; Nathaniel Melling; Ronald Simon; Christina Möller-Koop; Philipp Weigand; Sarah Minner; Alexander Haese; Hans Uwe Michl; Maria Christina Tsourlakis; Frank Jacobsen; Andrea Hinsch; Corinna Wittmer; Patrick Lebok; Stefan Steurer; Jakob R Izbicki; Guido Sauter; Till Krech; Franziska Büscheck; Till Clauditz; Thorsten Schlomm; Waldemar Wilczak
Journal:  Oncotarget       Date:  2017-05-09

6.  Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Authors:  Shashwat Sharad; Lakshmi Ravindranath; Michael C Haffner; Hua Li; Wusheng Yan; Isabell A Sesterhenn; Yongmei Chen; Amina Ali; Alagarsamy Srinivasan; David G McLeod; Srinivasan Yegnasubramanian; Shiv Srivastava; Albert Dobi; Gyorgy Petrovics
Journal:  Epigenetics       Date:  2014-04-02       Impact factor: 4.528

7.  NKAIN2 functions as a novel tumor suppressor in prostate cancer.

Authors:  Xueying Mao; Fei Luo; Lara K Boyd; Bowei Zhou; Yanling Zhang; Elzbieta Stankiewicz; Jacek Marzec; Natasa Vasiljevic; Yongwei Yu; Ninghan Feng; Jia Xu; Attila Lorincz; Yong Jiang; Claude Chelala; Guoping Ren; Daniel M Berney; Shan-Chao Zhao; Yong-Jie Lu
Journal:  Oncotarget       Date:  2016-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.